CSPC Pharmaceutical Group Limited (1093.HK)

Executive Summary

CSPC Pharmaceutical Group Limited (1093.HK) is a leading integrated pharmaceutical company in China, with core operations spanning branded generics, innovative drugs, and active pharmaceutical ingredients (APIs). The company's diverse portfolio covers key therapeutic areas such as oncology, cardiovascular, central nervous system, and anti-infectives. CSPC has been transitioning from a generics-focused business to an innovation-driven model, supported by a pipeline of seven drug candidates in clinical development. Notable pipeline assets include butylphthalide for ST-segment elevation myocardial infarction (STEMI) in Phase 3, and a Phase 2 combination regimen for acute myeloid leukemia (AML). The company also has a commercial product, pegylated liposomal doxorubicin, and a range of approved generics that provide steady revenue. CSPC's manufacturing facilities are certified to international standards (CGMP, EU GMP, FDA), enabling both domestic and export sales. Despite pricing pressures from China's Volume-Based Procurement (VBP) policy, CSPC has maintained a strong market position through its established brands and ongoing R&D investment. The company's financials remain solid, with a market cap of approximately $10.5 billion, and its strategy focuses on advancing its pipeline while optimizing its generics business for sustainable growth.

Upcoming Catalysts (preview)

• Q1 2026Phase 3 data readout for Butylphthalide in STEMI75% success
• Q4 2026Top-line results from Phase 2 AML trial (VCA regimen followed by D-MAG)60% success
• Q2 2026Potential NDA submission for Butylphthalide in new indication or expanded label70% success